EMA Authorised: Lazcluze (lazertinib mesilate monohydrate) — Janssen Cilag International NV

View source ↗

Summary

The European Medicines Agency authorised Lazcluze (lazertinib mesilate monohydrate) for non-small cell lung cancer, with Janssen Cilag International NV as the m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LAZCLUZE (LAZERTINIB)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Janssen Cilag International NV. Decision date: 12/02/2026